Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06523530 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of a GnRH Analog on Hepatic Steatosis

Study acronym: EndomMASLD
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v5
  2. Primary completion date: Oct 2026 to Apr 2027
    • Study completion date: Apr 2027 to Oct 2027
    • Site details revised at 2 of 2 sites
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 2024 to Nov 26, 2024
    • Site details revised at 2 of 2 sites
    v3
  4. Secondary endpoints: 20 to 22v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.
Trial Details
NCT Number NCT06523530
Lead Sponsor Aristotle University Of Thessaloniki
Collaborators: 424 General Military Hospital
Conditions
(from sponsor)		 Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis
Related terms Endometriosis, Liver Cirrhosis, Non-alcoholic Fatty Liver Disease
Enrollment 62 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov